SELL and rheumatoid arthritis: The results suggested that Myeloid DC AC (OR, 1.389; 95% CI, 1.013–1.065; P = 0.003; PFDR = 0.158), CD62L- myeloid DC AC (OR, 1.054; 95% CI, 1.017–1.092; P = 0.002; PFDR = 0.179), CD25 on IgD+ CD24+ (OR, 1.034; 95% CI, 1.013–1.056; P = 0.004; PFDR = 0.123), IgD on transitional (OR, 1.066; 95% CI, 1.024–1.109; P = 0.002; PFDR = 0.129), and CD45 on CD8br (OR, 1.012; 95% CI, 1.004–1.020; P = 0.004; PFDR = 0.173) may increase RA risk (Figure 2).